Experimental drug CBL-514 kills fat cells in early trials, reducing visceral fat by ~12%

Science News reports that MRI scans from a subset of participants in two small trials showed a 12 percent visceral-fat drop in the CBL-514 group four weeks after treatment, versus a nearly 6 percent gain with placebo. The drug triggers fat-cell death rather than simply shrinking the cells. Science News says it may help people resist weight regain after stopping weight-loss drugs; larger trials are testing its safety and efficacy.